Utomilumab, CAS 1417318-27-4

Product Description: Utomilumab (PF 05082566) is a fully human IgG2 mAb agonist of the T-cell costimulatory receptor 4-1BB/CD137. Utomilumab can be used for the research of relapsed/refractory follicular lymphoma (FL) and other CD20+ non-Hodgkin lymphomas (NHL)[1][2].

Applications: COVID-19-immunoregulation

Formula: C17H24N8O3

References: [1]Anthony W Tolcher, et al. Phase Ib Study of Utomilumab (PF-05082566), a 4-1BB/CD137 Agonist, in Combination with Pembrolizumab (MK-3475) in Patients with Advanced Solid Tumors. Clin Cancer Res. 2017 Sep 15;23(18):5349-5357./[2]Ajay K Gopal, et al. First-in-Human Study of Utomilumab, a 4-1BB/CD137 Agonist, in Combination with Rituximab in Patients with Follicular and Other CD20⁺ Non-Hodgkin Lymphomas. Clin Cancer Res. 2020 Jun 1;26(11):2524-2534.

CAS Number: 1417318-27-4

Molecular Weight: 388.42

Compound Purity: 99.20

Research Area: Cancer; Inflammation/Immunology

Solubility: H2O

Target: TNF Receptor

• Artikelnummer: MEXHY-P99056-1
• Hersteller: MedChemExpress
• Hersteller Artikelnummer: HY-P99056-1
• Green Labware: Nein
• Verpackungseinheit: 1 mg
• Mengeneinheit: STK